Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 52

Results For "C"

11240 News Found

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority
Drug Approval | May 15, 2026

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026


Telangana life sciences ecosystem reaches $145 billion valuation
Biotech | May 15, 2026

Telangana life sciences ecosystem reaches $145 billion valuation

The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters


Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
News | May 15, 2026

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives


OneSource records Rs. 4,282 million revenue in Q4 FY26
News | May 15, 2026

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold


Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26
News | May 15, 2026

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market


Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care
News | May 15, 2026

Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care

The target reach is of more than 30 million young people and caregivers across 21 countries


Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer
Clinical Trials | May 15, 2026

Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer

The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents


Alembic Pharma receives USFDA tentative approval for Darolutamide tablets
Drug Approval | May 15, 2026

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States


Merck to showcase 100+ oncology studies at 2026 ASCO meeting
R&D | May 14, 2026

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline